argenx SE header image

argenx SE

ARGX

Equity

ISIN NL0010832176 / Valor 24766616

Euronext - Euronext Brussels (2026-03-23)

EUR 588.20+0.58%

argenx SE
UMushroom community rating:

4.67 3 votes No rating yet

NegativeNeutralPositive

About company

Argenx SE is a biotechnology company that specializes in developing innovative therapies for the treatment of severe autoimmune diseases and cancer. The company leverages its proprietary technology platform to create a portfolio of first-in-class product candidates, which are developed in collaboration with academic partners. Argenx's approach focuses on translating breakthroughs in immunology into effective medicines, aiming to address unmet medical needs. The company's flagship product, efgartigimod, is designed to modulate the immune system and is being explored for multiple autoimmune indications. Argenx is headquartered in the Netherlands and operates globally, with a commitment to advancing its pipeline through rigorous research and development efforts.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

3.41%1Y

76.7%3Y

135%5Y

Performance

35.0%1Y

40.0%3Y

38.6%5Y

Volatility

42308 M

Market cap (USD)

151,507

Daily traded volume (Shares)

600 / 594.2

1 day high/low (USD)

0.00 / 0.00

52 weeks high/low (USD)

01 January, 2022

Dividend ex-date

0.00

Dividend (USD)

0.00%

Dividend yield (p.a.)

0.002022

0.002023

0.002024

Est dividend (USD)

0.00%2022

0.00%2023

0.00%2024

Est dividend yield

10.00

P/E ratio

00.002022

00.002023

00.002024

Est P/E ratio

0.00

EPS (USD)

0.002022

0.002023

0.002024

Est EPS (USD)

Ratings & reviews

4.67

3 votes

Performance:

4.33

Innovation:

5.00

Society:

4.67

Nature:

3.67

Laura Sofie Tohver

United Kingdom, 11 Nov 2025

Emerging technology and nice returns

Viktor Stockel

Switzerland, 30 Oct 2025

Argenx SE is a commercial-stage, global biopharmaceutical company focused on immunology, particularly therapies for severe autoimmune diseases.

Claudia Stadelmann

Switzerland, 05 Mar 2025

Geheimtipp belgisches Biotech mit spannender Pipeline

EQUITIES OF THE SAME SECTOR

Atos SE

Atos SE Valor: 167932

Annual Return

-50%0%+50%

Risk level

110

-1.93%EUR 38.03

Neurones

Neurones Valor: 837153

Annual Return

-50%0%+50%

Risk level

110

1.47%EUR 34.50

Tietoevry Oyj

Tietoevry Oyj Valor: 472478

Annual Return

-50%0%+50%

Risk level

110

-1.16%EUR 17.83

Revenio Group Oyj

Revenio Group Oyj Valor: 1304192

Annual Return

-50%0%+50%

Risk level

110

0.33%EUR 18.24

SAP SE

SAP SE Valor: 345952

Annual Return

-50%0%+50%

Risk level

110

0.03%EUR 153.86

SMA Solar Technology AG

SMA Solar Technology AG Valor: 4337414

Annual Return

-50%0%+50%

Risk level

110

-3.16%EUR 38.06

Biotest AG

Biotest AG Valor: 327343

Annual Return

-50%0%+50%

Risk level

110

0.00%EUR 36.20

NEXUS AG

NEXUS AG Valor: 1099292

Annual Return

-50%0%+50%

Risk level

110

-0.14%EUR 71.20

Coherent Corp

Coherent Corp Valor: 121251014

Annual Return

-50%0%+50%

Risk level

110

0.56%USD 255.05

DATAGROUP SE

DATAGROUP SE Valor: 2683224

Annual Return

-50%0%+50%

Risk level

110

0.27%EUR 73.20

SIX

FactSet

Clearbit

Logos provided by Clearbit